Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Watts

Showing results (681-690 of 701) with videos related to

Pageof 71
Sort By:
Blood Advances|February 1, 2023
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AMLStéphane de Botton, Pierre Fenaux, Karen Yee, et al.
Emerging Infectious Diseases|June 18, 2004
Endemic Venezuelan equine encephalitis in northern PeruPatricia V Aguilar, Ivorlyne P Greene, Lark L Coffey, et al.
The Lancet. Haematology|November 12, 2022
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trialJustin M Watts, Maria R Baer, Jay Yang, et al.
Leukemia Research|July 12, 2025
Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B‑8800 in lower-risk myelodysplastic syndromeJames M Foran, Guillermo F Sanz, Justin M Watts, et al.
Blood Advances|May 8, 2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLSung Choe, Hongfang Wang, Courtney D DiNardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2019
Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I TrialNaseema Gangat, Christian Marinaccio, Ronan Swords, et al.
Med (New York, N.Y.)|June 1, 2022
Cross-tissue, single-cell stromal atlas identifies shared pathological fibroblast phenotypes in four chronic inflammatory diseasesIlya Korsunsky, Kevin Wei, Mathilde Pohin, et al.
Blood|December 17, 2019
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemiaGail J Roboz, Courtney D DiNardo, Eytan M Stein, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 27, 2005
Prevalences, genotypes, and risk factors for HIV transmission in South AmericaSilvia M Montano, Jose L Sanchez, Alberto Laguna-Torres, et al.
Nature Immunology|May 8, 2019
Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometryFan Zhang, Kevin Wei, Kamil Slowikowski, et al.
Pageof 71

Showing results (681-690 of 701) with videos related to

Sort By:
Pageof 71
Blood Advances|February 1, 2023
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AMLStéphane de Botton, Pierre Fenaux, Karen Yee, et al.
Emerging Infectious Diseases|June 18, 2004
Endemic Venezuelan equine encephalitis in northern PeruPatricia V Aguilar, Ivorlyne P Greene, Lark L Coffey, et al.
The Lancet. Haematology|November 12, 2022
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trialJustin M Watts, Maria R Baer, Jay Yang, et al.
Leukemia Research|July 12, 2025
Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B‑8800 in lower-risk myelodysplastic syndromeJames M Foran, Guillermo F Sanz, Justin M Watts, et al.
Blood Advances|May 8, 2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLSung Choe, Hongfang Wang, Courtney D DiNardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2019
Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I TrialNaseema Gangat, Christian Marinaccio, Ronan Swords, et al.
Med (New York, N.Y.)|June 1, 2022
Cross-tissue, single-cell stromal atlas identifies shared pathological fibroblast phenotypes in four chronic inflammatory diseasesIlya Korsunsky, Kevin Wei, Mathilde Pohin, et al.
Blood|December 17, 2019
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemiaGail J Roboz, Courtney D DiNardo, Eytan M Stein, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 27, 2005
Prevalences, genotypes, and risk factors for HIV transmission in South AmericaSilvia M Montano, Jose L Sanchez, Alberto Laguna-Torres, et al.
Nature Immunology|May 8, 2019
Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometryFan Zhang, Kevin Wei, Kamil Slowikowski, et al.
Pageof 71